Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Hypolipoproteinemia causes

Introduction

Overview

Overview

Hypolipoproteinemia is due to genetic abnormalities or other diseases such as malnutrition and malabsorption, endocrine disorders, metabolic disorders, renal diseases or caused by drug side effects/toxicities.

Causes

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Causes Based on Major Lipoprotein Detected in Blood Laboratory Test

Low Cholesterol Causes

Low Chylomicron Causes

Low Chylomicron remnant Causes

Low Triglyceride Causes

Low HDL Causes

Low IDL Causes

Low LDL Causes

Low VLDL Causes

Combined List of Causes in Alphabetical Order

References

References

  1. ↑ 1.0 1.1 1.2 Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M; et al. (1992). “Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia”. Science. 258 (5084): 999–1001. PMID 1439810.
  2. ↑ 2.0 2.1 2.2 Weintraub M, Grosskopf I, Trostanesky Y, Charach G, Rubinstein A, Stern N (1999). “Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism”. J Clin Endocrinol Metab. 84 (7): 2532–6. PMID 10404832.
  3. ↑ 3.0 3.1 3.2 Scanu, AM.; Aggerbeck, LP.; Kruski, AW.; Lim, CT.; Kayden, HJ. (1974). “A study of the abnormal lipoproteins in abetalipoproteinemia”. J Clin Invest. 53 (2): 440–53. doi:10.1172/JCI107578. PMID 11344558. Unknown parameter |month= ignored (help)
  4. ↑ 4.0 4.1 4.2 Welty, FK.; Mittleman, MA.; Wilson, PW.; Sutherland, PA.; Matheney, TH.; Lipinska, I.; Muller, JE.; Levy, D.; Tofler, GH. (1997). “Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population”. Circulation. 95 (4): 825–30. PMID 9054738. Unknown parameter |month= ignored (help)
  5. ↑ 5.0 5.1 Tassiopoulos T, Stamatelos G, Zakopoulos N, Fessas P, Eliopoulos GD (1995). “Low incidence of acute myocardial infarction in beta-thalassaemia trait carriers”. Haematologia (Budap). 26 (4): 199–203. PMID 7590514.
  6. ↑ 6.0 6.1 Maioli M, Pettinato S, Cherchi GM, Giraudi D, Pacifico A, Pupita G; et al. (1989). “Plasma lipids in beta-thalassemia minor”. Atherosclerosis. 75 (2–3): 245–8. PMID 2712866.
  7. ↑ 7.0 7.1 Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (1997). “Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity”. Am J Hematol. 55 (3): 129–33. PMID 9256291.
  8. ↑ 8.0 8.1 Harris WS, Muzio F (1993). “Fish oil reduces postprandial triglyceride concentrations without accelerating lipid-emulsion removal rates”. Am J Clin Nutr. 58 (1): 68–74. PMID 8317392.
  9. ↑ 9.0 9.1 Harris WS, Hustvedt BE, Hagen E, Green MH, Lu G, Drevon CA (1997). “N-3 fatty acids and chylomicron metabolism in the rat”. J Lipid Res. 38 (3): 503–15. PMID 9101431.
  10. ↑ 10.0 10.1 10.2 10.3 10.4 10.5 Iannello S, Cavaleri A, Milazzo P, Cantarella S, Belfiore F (2003). “Low fasting serum triglyceride level as a precocious marker of autoimmune disorders”. MedGenMed. 5 (3): 20. PMID 14600656.
  11. ↑ 11.0 11.1 Achar S, Rostamian A, Narayan SM (2010). “Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm”. Am J Cardiol. 106 (6): 893–901. doi:10.1016/j.amjcard.2010.05.013. PMID 20816133.
  12. ↑ 12.0 12.1 Baggio, G; Manzato, E; Gabelli, C; Fellin, R; Martini, S; Enzi, G B; Verlato, F; Baiocchi, M R; Sprecher, D L; Kashyap, M L (1986). “Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients”. Journal of Clinical Investigation. 77 (2): 520–527. doi:10.1172/JCI112332. ISSN 0021-9738.
  13. ↑ 13.0 13.1 Cuisinier-Raynal JC, Bire F, Clerc M, Bernard J, Sarrouy J (1990). “[Human malaria: dysglobulinemia-hypocholesterolemia syndrome]”. Med Trop (Mars). 50 (1): 91–5. PMID 2366654.
  14. ↑ 14.0 14.1 Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C; et al. (2010). “Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia”. N Engl J Med. 363 (23): 2220–7. doi:10.1056/NEJMoa1002926. PMC 3008575. PMID 20942659.
  15. ↑ 15.0 15.1 Schaefer EJ, Ordovas JM, Law SW, Ghiselli G, Kashyap ML, Srivastava LS; et al. (1985). “Familial apolipoprotein A-I and C-III deficiency, variant II”. J Lipid Res. 26 (9): 1089–101. PMID 3934306.
  16. ↑ 16.0 16.1 Ito MK (2004). “The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin”. Ann Pharmacother. 38 (2): 277–85. doi:10.1345/aph.1D218. PMID 14742767.
  17. ↑ 17.0 17.1 17.2 17.3 17.4 17.5 Ashen, M. Dominique; Blumenthal, Roger S. (2005). “Low HDL Cholesterol Levels”. New England Journal of Medicine. 353 (12): 1252–1260. doi:10.1056/NEJMcp044370. ISSN 0028-4793.
  18. ↑ 18.0 18.1 Yamashita S, Matsuzawa Y (2009). “Where are we with probucol: a new life for an old drug?”. Atherosclerosis. 207 (1): 16–23. doi:10.1016/j.atherosclerosis.2009.04.002. PMID 19457483.
  19. ↑ 19.0 19.1 Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J (2004). “Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C”. Curr Med Res Opin. 20 (7): 1087–94. doi:10.1185/030079904125004105. PMID 15265253.
  20. ↑ 20.0 20.1 Wakatsuki A, Okatani Y, Ikenoue N (2000). “Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia”. Atherosclerosis. 150 (1): 103–11. PMID 10781640.
  21. ↑ 21.0 21.1 Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y (2012). “Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia”. J Clin Lipidol. 6 (3): 235–43. doi:10.1016/j.jacl.2011.11.004. PMID 22658147.
  22. ↑ 22.0 22.1 Forte TM, Nichols AV, Krauss RM, Norum RA (1984). “Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis”. J Clin Invest. 74 (5): 1601–13. doi:10.1172/JCI111576. PMC 425337. PMID 6501564.
  23. ↑ 23.0 23.1 Mack WJ, Krauss RM, Hodis HN (1996). “Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression”. Arterioscler Thromb Vasc Biol. 16 (5): 697–704. PMID 8963728.
  24. ↑ 24.0 24.1 Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). “Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients”. Kidney Int Suppl. 71: S134–6. PMID 10412757.
  25. ↑ 25.0 25.1 Lee SJ, Sacks FM (2003). “Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus”. Am J Cardiol. 92 (2): 121–4. PMID 12860210.
  26. ↑ 26.0 26.1 Sari I, Bakir S, Engin A, Aydin H, Poyraz O (2013). “Some acute phase reactants and cholesterol levels in serum of patient with Crimean-Congo haemorrhagic fever”. Bosn J Basic Med Sci. 13 (1): 21–6. PMID 23448606.
  27. ↑ 27.0 27.1 Kim HJ, Moon JH, Kim HM, Yun MR, Jeon BH, Lee B; et al. (2013). “The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression”. Metabolism. doi:10.1016/j.metabol.2013.09.006. PMID 24139096.
  28. ↑ 28.0 28.1 Xiong W, Gu L, Wang C, Sun H, Liu X (2013). “Anti-hyperglycemic and hypolipidemic effects of Cistanche tubulosa in type 2 diabetic db/db mice”. J Ethnopharmacol. doi:10.1016/j.jep.2013.09.027. PMID 24095831.
  29. ↑ 29.0 29.1 Maitin V, Andreo U, Guo L, Fisher EA (2013). “Docosahexaenoic Acid Impairs the Maturation of Very Low Density Lipoproteins in Rat Hepatic Cells”. J Lipid Res. doi:10.1194/jlr.M043026. PMID 24136824.
  30. ↑ 30.0 30.1 Søndergaard E, Poulsen MK, Jensen MD, Nielsen S (2013). “Acute changes in lipoprotein subclasses during exercise”. Metabolism. doi:10.1016/j.metabol.2013.08.011. PMID 24075739.
  31. ↑ 31.0 31.1 Zhang Y, Zhang L, Geng Y, Geng Y (2013). “Hawthorn Fruit Attenuates Atherosclerosis by Improving the Hypolipidemic and Antioxidant Activities in Apolipoprotein E-Deficient Mice”. J Atheroscler Thromb. PMID 24126122.
  32. ↑ 32.0 32.1 Rojas A, Del Campo JA, Maraver M, Aparcero R, García-Valdecasas M, Diago M; et al. (2013). “Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro”. J Viral Hepat. doi:10.1111/jvh.12209. PMID 24188401.
  33. ↑ 33.0 33.1 Wei Q, Wang H, Tian Y, Xu F, Chen X, Wang K (2013). “Reduced serum levels of triglyceride, very low density lipoprotein cholesterol and apolipoprotein B in Parkinson’s disease patients”. PLoS One. 8 (9): e75743. doi:10.1371/journal.pone.0075743. PMC 3784418. PMID 24086623.
  34. ↑ 34.0 34.1 Liang YJ, Wang HP, Long DX, Li W, Wu YJ (2013). “A metabonomic investigation of the effects of 60days exposure of rats to two types of pyrethroid insecticides”. Chem Biol Interact. 206 (2): 302–308. doi:10.1016/j.cbi.2013.10.002. PMID 24121187.
  35. ↑ 35.0 35.1 Dash S, Xiao C, Morgantini C, Szeto L, Lewis GF (2013). “High-Dose Resveratrol Treatment for 2 Weeks Inhibits Intestinal and Hepatic Lipoprotein Production in Overweight/Obese Men”. Arterioscler Thromb Vasc Biol. doi:10.1161/ATVBAHA.113.302342. PMID 24072699.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]